Cancer glossary
Nivolumab (Opdivo): how it works, which cancers and side effects
Nivolumab is an immunotherapy drug, a PD-1 inhibitor. How it works, which cancers it is used for, how often it is given and how the combination with ipilimumab differs.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 19 October 2026
In short
Nivolumab (brand name Opdivo) is an immunotherapy drug from the group of immune checkpoint inhibitors. Like pembrolizumab, it blocks PD-1 and helps the immune system recognize the tumor.
How it appears in your prescription
- ‘Nivolumab 240 mg every 2 weeks’ or ‘480 mg every 4 weeks’.
- ‘Nivolumab + ipilimumab’ — a combination of two immunotherapy drugs.
- ‘Nivolumab + chemotherapy’ — for example, in stomach and esophageal cancer.
What it means
According to the US National Cancer Institute, nivolumab is approved for melanoma, non-small cell lung cancer, kidney, head and neck, bladder, esophageal and stomach cancer, MSI-H/dMMR colorectal cancer and several other tumors. It is used both after surgery and for advanced disease. Approved uses in each country are set by the local label and guidelines.
On immunotherapy, scans sometimes first show lesions growing and later shrinking — this is pseudoprogression. That is why the first follow-up scan is interpreted with caution.
Side effects
Fatigue, rash and itching, diarrhea, changes in thyroid function. Most important are immune-related adverse events: colitis, hepatitis, pneumonitis and damage to hormone glands. With ipilimumab they are noticeably more common.
Tell your doctor straight away about frequent diarrhea or blood in the stool, cough and shortness of breath, yellowing of the skin, severe weakness and dizziness.
Questions to ask your doctor
- Single drug or combination — and why?
- How often are the infusions and how long will treatment last?
- When is the first scan, and how will pseudoprogression be told apart from progression?
Sources
- Nivolumab — National Cancer Institute
- Side Effects of Immunotherapy — National Cancer Institute
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update — ASCO, 2021
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
